Journal article · 2026

Design, Synthesis, and Biological Evaluation of Indolin-2-one Derivatives as Novel Covalent Pan-FGFR Inhibitors for Overcoming Clinical Resistance

Wenjian Zhu, Jing Guo, 颜玲, Xiaojing Lin, Xiaojuan Chen, Xiaojuan Song, Wuqing Deng, Yixin Luo, Zhengchao Tu, Yongheng Chen, Jeff Bruce Smaill, Adam Vorn Patterson and 1 more

Journal of Medicinal Chemistry · Published 7 November 2026 · DOI 10.1021/acs.jmedchem.6c02574

View at the publisherCite this paper

In brief

“Design, Synthesis, and Biological Evaluation of Indolin-2-one Derivatives as Novel Covalent Pan-FGFR Inhibitors for Overcoming Clinical Resistance” is a 2026 journal article by Wenjian Zhu and 12 co-authors, published in Journal of Medicinal Chemistry. OpenAlex counts 0 citations as of 16 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
0
References
32
Authors
13

Abstract

Oncogenic FGFR alterations drive the development of multiple cancers. However, acquired resistance to clinically approved inhibitors mediated by gatekeeper and molecular brake mutations poses a major therapeutic challenge. Herein, we describe the structure-based discovery of (Z)-3-(amino(phenyl)methylene)indolin-2-one derivatives as potent covalent pan-FGFR inhibitors. The representative compound, 9v, displayed high potency against FGFR1/2/3/4 (IC50 = 8.6, 5.4… Read the full abstract at the publisher.

Excerpt. This paper is not open access.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Zhu, W., Guo, J., 颜玲, Lin, X., Chen, X., Song, X., Deng, W., Luo, Y., Tu, Z., Chen, Y., Smaill, J. B., Patterson, A. V., & Lu, X. (2026). Design, Synthesis, and Biological Evaluation of Indolin-2-one Derivatives as Novel Covalent Pan-FGFR Inhibitors for Overcoming Clinical Resistance. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c02574

MLA 9

Zhu, Wenjian, et al. “Design, Synthesis, and Biological Evaluation of Indolin-2-one Derivatives as Novel Covalent Pan-FGFR Inhibitors for Overcoming Clinical Resistance.” Journal of Medicinal Chemistry, 2026. https://doi.org/10.1021/acs.jmedchem.6c02574.

Chicago

Zhu, Wenjian, Jing Guo, 颜玲, Xiaojing Lin, Xiaojuan Chen, Xiaojuan Song, Wuqing Deng, et al. 2026. “Design, Synthesis, and Biological Evaluation of Indolin-2-one Derivatives as Novel Covalent Pan-FGFR Inhibitors for Overcoming Clinical Resistance.” Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c02574.

Harvard

Zhu, W. et al. (2026) ‘Design, Synthesis, and Biological Evaluation of Indolin-2-one Derivatives as Novel Covalent Pan-FGFR Inhibitors for Overcoming Clinical Resistance’, Journal of Medicinal Chemistry. doi:10.1021/acs.jmedchem.6c02574.

IEEE

W. Zhu et al., “Design, Synthesis, and Biological Evaluation of Indolin-2-one Derivatives as Novel Covalent Pan-FGFR Inhibitors for Overcoming Clinical Resistance,” Journal of Medicinal Chemistry, 2026, doi: 10.1021/acs.jmedchem.6c02574.

BibTeX

@article{zhu2026design,
  title     = {{Design, Synthesis, and Biological Evaluation of Indolin-2-one Derivatives as Novel Covalent Pan-FGFR Inhibitors for Overcoming Clinical Resistance}},
  author    = {Zhu, Wenjian and Guo, Jing and 颜玲 and Lin, Xiaojing and Chen, Xiaojuan and Song, Xiaojuan and Deng, Wuqing and Luo, Yixin and Tu, Zhengchao and Chen, Yongheng and Smaill, Jeff Bruce and Patterson, Adam Vorn and Lu, Xiaoyun},
  journal   = {Journal of Medicinal Chemistry},
  year      = {2026},
  doi       = {10.1021/acs.jmedchem.6c02574},
  url       = {https://doi.org/10.1021/acs.jmedchem.6c02574}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research

  • indolin-2-one derivatives
  • fibroblast growth factor receptor
  • acquired drug resistance
  • gatekeeper mutation
  • FGFR3
  • structure-based drug design
  • bladder cancer
  • antiproliferative activity

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Zhu, W., Guo, J., 颜玲, Lin, X., Chen, X., Song, X., Deng, W., Luo, Y., Tu, Z., Chen, Y., Smaill, J. B., Patterson, A. V., & Lu, X. (2026). Design, Synthesis, and Biological Evaluation of Indolin-2-one Derivatives as Novel Covalent Pan-FGFR Inhibitors for Overcoming Clinical Resistance. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c02574

How many times has this paper been cited?

0 times, according to OpenAlex on 16 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

Who wrote this paper?

Wenjian Zhu, Jing Guo, 颜玲, Xiaojing Lin, Xiaojuan Chen, Xiaojuan Song, Wuqing Deng, Yixin Luo, Zhengchao Tu, Yongheng Chen, Jeff Bruce Smaill, Adam Vorn Patterson and 1 more.

What is the DOI of this paper?

10.1021/acs.jmedchem.6c02574, permanently at https://doi.org/10.1021/acs.jmedchem.6c02574. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 16 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.